Icatibant Wockhardt Uk

Icatibant acetate, the active ingredient in Icatibant Wockhardt Uk, is a bradykinin B2 receptor antagonist presented as a sterile injection solution for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, helping to reduce swelling and associated discomfort.

GNH USA supplies Icatibant Wockhardt Uk as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, specialty pharmacies, transplant centres and clinical clinics worldwide, with support for regulatory documentation and cold‑chain logistics where required.

Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema. - Acute attacks of hereditary angioedema (C1 inhibitor deficiency): rapid reduction of swelling and pain. - Hereditary angioedema type I: alleviates edema during flare‑ups. - Hereditary angioedema type II: provides prompt symptom control.

Icatibant may cause a range of adverse reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: occasional feeling of queasiness. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness. - Flushing: temporary warmth and reddening of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of face, lips, or throat. - Hypotension: sudden drop in blood pressure. - Severe allergic reaction: including rash, itching, or swelling. - Thrombocytopenia: low platelet count observed in rare cases.

Before using icatibant, consider the following safety measures. - Pregnancy: safety not established; use only if the potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; caution is advised. - Renal impairment: no specific dose adjustment, but monitor for accumulation. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced angioedema risk. - Hypersensitivity: discontinue immediately if a severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effects may raise the risk of angioedema. - Angiotensin receptor blockers (ARBs): similar potential for increased angioedema.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate edema or interfere with pain control. - Estrogen‑containing oral contraceptives: can worsen hereditary angioedema severity. - Diuretics: monitor blood pressure and volume status during treatment.